<DOC>
	<DOCNO>NCT00400114</DOCNO>
	<brief_summary>The purpose study see whether combination cisplatin , irinotecan radiation , follow surgery , follow oral Sutent , effective safe patient resectable esophageal cancer .</brief_summary>
	<brief_title>Sutent Following Chemotherapy , Radiation Surgery For Resectable Esophageal Cancer</brief_title>
	<detailed_description>Survival outcomes resectable esophageal cancer remain poor . Current data strongly support adjuvant systemic strategy improve time progression survival patient population . Adding well-tolerated oral target therapy Sutent , combine chemo/radiation/surgery approach patient population potential impact minimal residual disease leave behind relatively effective pre-operative chemoradiation surgery . This potential improve survival . The primary endpoint determine feasibility efficacy adjuvant Sutent therapy ( SU11248 ) concurrent neoadjuvant therapy irinotecan , cisplatin , external beam conformal radiotherapy plus surgery potential resectable esophageal cancer . Preclinical clinical data suggest Sutent activity esophageal cancer , result Sutent activity solid tumor appear superior result antiangiogenic compound development esophageal cancer . Therefore , extrapolation promise phase I , II III Sutent trial propose translate target effect achieve Sutent reduce local systemic therapy failure , thus metastasis esophageal cancer .</detailed_description>
	<mesh_term>Esophageal Neoplasms</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Sunitinib</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<criteria>Histologically proven squamous adenocarcinoma esophagus &gt; 20 cm incisor , include GE junction tumor ( unless gastric origin ) . Tumors must technically resectable . Clinical T1N1M0 , T23 N01 M0 Performance status ECOG 01 Medically fit chemotherapy , radiation esophagectomy In situ clinical T1N0M0 , stage IV ( M1a orM1b ) Cervical esophageal tumor ( within 20 cm incisor ) Age &lt; 18 &gt; 70 Participation another concurrent clinical study involve study drug ( ) treatment study drug within thirty day prior treatment study . Concurrent treatment experimental drug anticancer therapy know suspected drug alcohol abuse Prior treatment malignancy except esophageal stenting</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>esophageal</keyword>
	<keyword>esophagus</keyword>
	<keyword>cancer</keyword>
	<keyword>sutent</keyword>
	<keyword>sunitinib</keyword>
</DOC>